This is the authors' abstract. We don't add key points for this paper.
These data raise awareness of SPM as a clinically relevant long-term adverse event in patients receiving CAR T-cell therapy. However, our findings do not indicate that SPM frequency is higher with CAR-T versus previous standard-of-care strategies.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Tix et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: